More than half of study participants were enrolled in the patient portal and 98% were classified as passive users, but only moderately active use of the patient portal was associated with a reduced risk of readmission.
Results from the systematic review and meta-analysis demonstrated the positive effect of DAA therapy on overall survival, HCC-free survival, and liver function among patients with HCV decompensated cirrhosis compared to a non-DAA control group.
Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review.